Long-acting Fc-fusion fibroblast growth factor 21 (FGF21) analog with direct antifibrotic, anti-steatotic, and metabolic regulatory activity
An engineered, once-monthly IgG1-Fc-fused FGF21 analog developed by Novartis and advanced through Boston Pharmaceuticals and GSK for the treatment of metabolic dysfunction-associated steatohepatitis, distinguished from other FGF21 analogs by a 21-day pharmacokinetic half-life that permits monthly subcutaneous dosing and by Phase 2 evidence of fibrosis reversal and MASH resolution in patients with moderate-to-advanced hepatic fibrosis.
Abstract
Efimosfermin alfa (formerly LLF580 under Novartis origination, subsequently designated BOS-580 under Boston Pharmaceuticals development, and now GSK-6519754 following acquisition by GSK plc) is a genetically engineered, long-acting analog of human fibroblast growth factor 21 (FGF21), a hepatokine and adipokine that regulates hepatic lipid oxidation, adipose tissue glucose uptake, triglyceride metabolism, and inflammatory signaling through formation of a ternary complex with the transmembrane tyrosine kinase FGF receptor 1c (FGFR1c) and the obligate co-receptor beta-klotho (KLB). The molecule is a homodimeric fusion protein in which two copies of a stabilized FGF21 variant are fused at their N-termini to the crystallizable fragment (Fc) of human immunoglobulin G1 (IgG1). The FGF21 domain is further stabilized by the introduction of a non-native disulfide bond and point mutations that increase proteolytic resistance, together producing a pharmacokinetic half-life of approximately 21 days in humans and enabling subcutaneous administration once every four weeks. This dosing interval distinguishes efimosfermin from the weekly-dosed FGF21 analogs efruxifermin (Akero Therapeutics) and pegozafermin (89bio), which require subcutaneous injection every one to two weeks.
In May 2025, GSK plc completed acquisition of efimosfermin from Boston Pharmaceuticals for 1.2 billion United States dollars upfront and up to 800 million dollars in milestone payments, with tiered royalties owed to Novartis Pharma AG. The compound has received United States Food and Drug Administration Breakthrough Therapy Designation and European Medicines Agency Priority Medicines (PRIME) Designation for the treatment of MASH. Phase 3 development (the ZENITH program) commenced in December 2025, with a potential first launch projected for 2029. GSK has indicated development plans in both MASH (including compensated cirrhosis) and alcohol-related liver disease (ALD), with potential for combination therapy with GSK’990, a complementary hepatology pipeline candidate. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.